NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS FOR THE LATE PRECLINICAL DEVELOPMENT OF THE FIRST-IN-CLASS ANTIBIOTIC NOSO-502 

An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results allow for the further development of the program to Phase 1  Utrecht, the Netherlands, and Lyon, France, 8 June 2022  Nosopharm, a biotechnology company specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces the completion and positive results of toxicology studies for NOSO-502, a first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. NOSO-502 is being developed by Nosopharm in partnership with GNA NOW, a European Consortium funded by the Innovative Medicines Initiative 2 (IMI2).   NOSO-502 is the first clinical candidate in the new class of antibiotics called Odilorhabdins. It was discovered by Nosopharm from a Xenorhabdus bacteria. NOSO-502 is intended for the treatment of the main hospital-acquired infections caused by the multidrug-resistant Enterobacterales: Escherichia coli, Klebsiella

learn more

Nosopharm signs strategic partnership with INRAE and the university of Montpellier

Collaboration aims to produce chemical libraries of bioactive molecules that will feed into Nosopharm’s anti-infective screening procedures Nosopharm and its partner, the DGIMI laboratory (UMR INRAE—University of Montpellier), hope to establish joint laboratory in 2023 Lyon, France, March 15, 2022—Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces that it has signed a collaboration agreement with the DGIMI laboratory (UMR1333: Diversity, Genomes and Insects-Microorganisms Interactions). DGIMI falls under the authority of the French National Research Institute for Agriculture, Food, and the Environment (INRAE) and the University of Montpellier. The aim of this collaboration is to produce chemical libraries of new bioactive molecules which will feed into Nosopharm’s anti-infective screening campaigns against antibiotic resistance. ‘France Relance’, the French government investment plan created following the Covid-19 pandemic, brings financial support to this new collaboration between Nosopharm, INRAE and University of Montpellier. Nosopharm and

learn more

NOSOPHARM OBTAINS US PATENT FOR NOSO-502A, A FIRST-IN-CLASS NOVEL ANTIBIOTIC

Patent secures US market exclusivity for Nosopharm and covers numerous chemical analogs, reinforcing protection of NOSO-502’s chemical space Lyon, France, April 22, 2020 – Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces it has been granted a US patent for NOSO-502. NOSO-502 is Nosopharm’s first clinical candidate in a new class of antibiotics called Odilhorhabdins, aimed at eradicating resistant bacteria. This patent secures Nosopharm’s market exclusivity rights in the US, the leading pharmaceutical market. It also covers numerous chemical analogs – the chemical space of NOSO-502 – thereby reinforcing its protection against exploitation by competitors. Besides the US patent (US Patent No. 10,626,144), Nosopharm has been granted a patent in Russia, and a notice of acceptance has recently been issued in Australia. In addition, the company has filed patent applications in Canada, China, Europe (EPO), Japan, Hong Kong, Brazil, South Korea,

learn more